508 related articles for article (PubMed ID: 26334220)
1. Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib.
Yamamoto Y; Okamoto I; Otsubo K; Iwama E; Hamada N; Harada T; Takayama K; Nakanishi Y
Invest New Drugs; 2015 Oct; 33(5):1148-50. PubMed ID: 26334220
[TBL] [Abstract][Full Text] [Related]
2. Interstitial lung disease induced by alectinib (CH5424802/RO5424802).
Ikeda S; Yoshioka H; Arita M; Sakai T; Sone N; Nishiyama A; Niwa T; Hotta M; Tanaka T; Ishida T
Jpn J Clin Oncol; 2015 Feb; 45(2):221-4. PubMed ID: 25398579
[TBL] [Abstract][Full Text] [Related]
3. Case report: continued treatment with alectinib is possible for patients with lung adenocarcinoma with drug-induced interstitial lung disease.
Nitawaki T; Sakata Y; Kawamura K; Ichikado K
BMC Pulm Med; 2017 Dec; 17(1):173. PubMed ID: 29207989
[TBL] [Abstract][Full Text] [Related]
4. Successful oral desensitization against skin rash induced by alectinib in a patient with anaplastic lymphoma kinase-positive lung adenocarcinoma: A case report.
Shirasawa M; Kubotaa M; Harada S; Niwa H; Kusuhara S; Kasajima M; Hiyoshi Y; Ishihara M; Igawa S; Masuda N
Lung Cancer; 2016 Sep; 99():66-8. PubMed ID: 27565916
[TBL] [Abstract][Full Text] [Related]
5. Alectinib (Alecensa)-induced reversible grade IV nephrotoxicity: a case report and review of the literature.
Ramachandran P; Morcus R; Tahir M; Onukogu I; Spinowitz B; Wang JC
J Med Case Rep; 2018 Oct; 12(1):303. PubMed ID: 30336782
[TBL] [Abstract][Full Text] [Related]
6. Interstitial lung disease secondary to alectinib after interstitial injury induced by crizotinib.
Kaira K; Naruse I; Shimizu K; Asao T
J Cancer Res Ther; 2020; 16(4):919-921. PubMed ID: 32930141
[TBL] [Abstract][Full Text] [Related]
7. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Hida T; Nokihara H; Kondo M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Imamura F; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Asabe R; Tanaka T; Tamura T
Lancet; 2017 Jul; 390(10089):29-39. PubMed ID: 28501140
[TBL] [Abstract][Full Text] [Related]
8. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Peters S; Camidge DR; Shaw AT; Gadgeel S; Ahn JS; Kim DW; Ou SI; Pérol M; Dziadziuszko R; Rosell R; Zeaiter A; Mitry E; Golding S; Balas B; Noe J; Morcos PN; Mok T;
N Engl J Med; 2017 Aug; 377(9):829-838. PubMed ID: 28586279
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment with alectinib after crizotinib-induced interstitial lung disease.
Chino H; Sekine A; Kitamura H; Kato T; Ogura T
Lung Cancer; 2015 Dec; 90(3):610-3. PubMed ID: 26452431
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary Adenocarcinoma, Harboring Both an EGFR Mutation and ALK Rearrangement, Presenting a Stable Disease to Erlotinib and a Partial Response to Alectinib.
Yokoyama A; Tamura A; Miyakawa K; Kusaka K; Shimada M; Hirose T; Matsui H; Kitani M; Hebisawa A; Ohta K
Intern Med; 2018 Aug; 57(16):2377-2382. PubMed ID: 29526950
[TBL] [Abstract][Full Text] [Related]
11. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
[TBL] [Abstract][Full Text] [Related]
12. Alectinib for the treatment of ALK-positive stage IV non-small cell lung cancer.
Wong KM; Noonan S; O'Bryant C; Jimeno A
Drugs Today (Barc); 2015 Mar; 51(3):161-70. PubMed ID: 25876560
[TBL] [Abstract][Full Text] [Related]
13. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort.
Bedas A; Peled N; Maimon Rabinovich N; Mishaeli M; Shochat T; Zer A; Rotem O; Allen AM; Bar J; Dudnik E;
Oncol Res Treat; 2019; 42(5):275-282. PubMed ID: 30955009
[TBL] [Abstract][Full Text] [Related]
15. Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study.
Ito K; Hataji O; Kobayashi H; Fujiwara A; Yoshida M; D'Alessandro-Gabazza CN; Itani H; Tanigawa M; Ikeda T; Fujiwara K; Fujimoto H; Kobayashi T; Gabazza EC; Taguchi O; Yamamoto N
J Thorac Oncol; 2017 Feb; 12(2):390-396. PubMed ID: 27498387
[TBL] [Abstract][Full Text] [Related]
16. Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP.
Tamura T; Kiura K; Seto T; Nakagawa K; Maemondo M; Inoue A; Hida T; Yoshioka H; Harada M; Ohe Y; Nogami N; Murakami H; Kuriki H; Shimada T; Tanaka T; Takeuchi K; Nishio M
J Clin Oncol; 2017 May; 35(14):1515-1521. PubMed ID: 28296581
[TBL] [Abstract][Full Text] [Related]
17. Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.
Zhu V; Ou SH
Expert Opin Drug Saf; 2017 Apr; 16(4):509-514. PubMed ID: 28276856
[TBL] [Abstract][Full Text] [Related]
18. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
Ou SH; Greenbowe J; Khan ZU; Azada MC; Ross JS; Stevens PJ; Ali SM; Miller VA; Gitlitz B
Lung Cancer; 2015 May; 88(2):231-4. PubMed ID: 25736571
[TBL] [Abstract][Full Text] [Related]
19. Successful re-introduction of alectinib after inducing interstitial lung disease in a patient with lung cancer.
Hwang A; Iskandar A; Dasanu CA
J Oncol Pharm Pract; 2019 Sep; 25(6):1531-1533. PubMed ID: 30572795
[TBL] [Abstract][Full Text] [Related]
20. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
Shaw AT; Gandhi L; Gadgeel S; Riely GJ; Cetnar J; West H; Camidge DR; Socinski MA; Chiappori A; Mekhail T; Chao BH; Borghaei H; Gold KA; Zeaiter A; Bordogna W; Balas B; Puig O; Henschel V; Ou SI;
Lancet Oncol; 2016 Feb; 17(2):234-242. PubMed ID: 26708155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
